Abstract
BACKGROUND: The development of neutralizing anti-factor VIII alloantibodies (inhibitors) in patients with severe hemophilia A may depend on the concentrate used for replacement therapy. METHODS We conducted a randomized trial to assess the incidence of factor VIII inhibitors among patients treated with plasma-derived factor VIII containing von Willebrand factor or recombinant factor VIII. Patients who met the eligibility criteria (male sex, age
Original language | English |
---|---|
Pages (from-to) | 2054-2064 |
Number of pages | 11 |
Journal | New England Journal of Medicine |
Volume | 374 |
Issue number | 21 |
DOIs | |
Publication status | Published - May 26 2016 |
ASJC Scopus subject areas
- Medicine(all)